Catharina hospital Eindhoven
Eindhoven, Netherlands
NCT Number: NCT06051110
Patients with a non-ST-segment elevation acute coronary syndrome (NSTE-ACS) are currently transported and admitted to the nearest emergency department (ED) for risk stratification, diagnostic workup, and treatment. Recently, several prospective studies have been performed on the diagnostic performance of point-of-care (POC)-troponin and combined risk scores (CRS) for pre-hospital risk assessment and triage of NSTE-ACS patients. Also the first intervention trials on triage decisions based on POC troponin and CRS have been performed. Initial results are indicating that prehospital triage based on these diagnostic tools is feasible and safe, although sample sizes were relatively small and underpowered to detect differences in major adverse cardiac events (MACE). The objective of this individual patient data meta-analysis is to determine the diagnostic performance of POC troponin and combined risk scores for prehospital risk assessment and triage in suspected NSTE-ACS patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Eindhoven, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin
Prehospital risk stratification by EMS protocols
Prehospital risk stratification by the use of a POC-troponin
Time frame: During index hospitalization, up to 1 day in the ED
Diagnosis of NSTE-ACS (NSTEMI or unstable AP) during index hospitalization (as assessed by the treating physician)
Time frame: Within 30 days
All cause death, myocardial infarction, revascularization
Time frame: 1 week
All cause death, myocardial infarction, revascularization
Time frame: Within 30 days and 1 year follow-up
Time frame: During or after index hospitalisation, up to 30 days
Time frame: During or after index hospitalisation, up to 30 days
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
Time frame: during 30 day follow-up after inclusion
If no NSTE-ACS is diagnosed, what is the alternative diagnosis (such as pulmonary embolism, aortic dissection, pneumothorax)
Time frame: during 30 day follow-up after intracoronary angiography and/or PCI
Bleeding complications
Time frame: during 30 day follow-up after intracoronary angiography and/or PCI
Contrast-induced nephropathy Possible or definite stent thrombosis Ischemic stroke Death
Time frame: during 30 day follow-up after intracoronary angiography and/or PCI
Possible or definite stent thrombosis
Time frame: during 30 day follow-up after intracoronary angiography and/or PCI
Ischemic stroke
Time frame: during 30 day follow-up after intracoronary angiography and/or PCI
Death
Time frame: Within 30 days after inclusion
Number of ambulance transfers
Time frame: Up to 30 days after inclusion
Duration of hospitalisation (days)
Time frame: Within 30 days after inclusion
Number of double invasive coronary angiography procedures
Time frame: At 30 days
Catharina Ziekenhuis Eindhoven
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06255678
Acute Coronary Syndrome, Cardiovascular Diseases
Warsaw, Poland
View Trial DetailsNCT06096909
Acute Coronary Syndrome, Cardiovascular Diseases
View Trial DetailsNCT05853042
Acute Coronary Syndrome, Acute Myocardial Infarction
Minneapolis, Minnesota, United States
View Trial DetailsNCT05992259
Acute Coronary Syndrome, Arrhythmias, Cardiac
Krasnodar, Russia
View Trial Details